Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap)

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2371-2376

  Dearden, S ^a   Stevens, J ^a   Wu, Y L ^b   Blowers, D ^a  

^a ASTRAZENECA   (United Kingdom)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Geography; Histology; Lung cancer; Mutation coincidence; Oncogenes

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN KINASE LKB1; PROTEIN P53;

ARTICLE; ASIAN; BRAF GENE; EGFR GENE; EML4 ALK GENE; ERBB2 GENE; ETHNICITY; GENE FREQUENCY; GENE MUTATION; GEOGRAPHY; HISTOLOGY; HUMAN; INCIDENCE; LKB1 GENE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; SMOKING; TP53 GENE; WESTERN HEMISPHERE;

GEOGRAPHY; HISTOLOGY; LUNG CANCER; MUTATION COINCIDENCE; ONCOGENES;

ADENOCARCINOMA; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHROMOSOME MAPPING; GENE FREQUENCY; HUMANS; INCIDENCE; LUNG NEOPLASMS; MUTATION; MUTATION RATE; SEQUENCE ANALYSIS, DNA; SMOKING;

EID: 84883347910     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt205     Document Type: Article

References (28)

1. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3: 819-831.
2. Rodenhuis S, van de Wetering ML, Mooi WJ et al. Mutational activation of the Kras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987; 317: 929-935.
3. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012; 22: 436-445.
4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
7. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
8. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
9. Greulich H. The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer 2010; 1: 1200-1210.
10. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
11. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-8092.
12. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
13. An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012; 7: e40109.
14. Liu P, Morrison C, Wang L, et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 2012; 33: 1270-1276.
15. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170.
16. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucl Acids Res 2011; 39(Suppl. 1): D945-D950.
17. Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med 2004; 10: 481-486.
18. Lam WK, White NW, Chan-Yeung MM. Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis 2004; 8: 1045-1057.
19. Trial of erlotinib and BKM120 in patients with advanced non small cell lung cancer previously sensitive to erlotinib; http://www.clinicaltrials.gov/ct2/show/NCT01487265 (7 March 2013, date last accessed).
20. Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 2011; 102: 1032-1037.
21. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93. Errata in: Sci Transl Med 2012; 4: 130er2. Sci Transl Med 2011; 3: 66er2.
22. National Cancer Institute. The Cancer Genome Atlas; updated 2011; http://cancergenome.nih.gov/(22 November 2011, date last accessed).
23. Hammerman PS, Hayes DN, Wilkerson MD, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
24. Thomas R. Identifying clinically relevant cancer genome alterations in lung cancer: The Clinical Lung Cancer Genome Project initiative; updated 2010; http://www. abstractsonline.com/plan/ViewAbstract.aspx?mID=2626&sKey=9269f5cb-5ea2-48c1-996d-e95d7b1d265e&cKey=7983f06c-92c1-4149-bf81-f7b64bcd8288&mKey=%7BE69F27FB-E294-49DA-92AC-DFC241A99F23%7D (21 September 2011, date last accessed).
25. Arrieta O, Cardona AF, Federico Bramuglia G, et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 2011; 6: 1955-1959.
26. National Comprehensive Cancer Network. Practice guidelines in oncology -version V.3.2012 (non-small-cell lung cancer); updated 2012; http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (6 December 2011, date last accessed).
27. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12: 6494-6501.
28. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12: 5764-5769.